ADRIANA ACOSTA: Open Payments
NPI 1871693986 · CORAL SPRINGS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,459 in 112 payments from 16 companies in 2025. Trend: 2023 $2,514 · 2024 $2,228 · 2025 $2,459
Food & beverage: $2,459
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 16 | $408 |
| ABBVIE INC. | 32 | $400 |
| GENZYME CORPORATION | 10 | $349 |
| Janssen Biotech, Inc. | 11 | $255 |
| Ardelyx, Inc. | 11 | $247 |
| Ethicon US, LLC | 1 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| Gilead Sciences, Inc. | 4 | $102 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $101 |
| Aimmune Therapeutics, Inc. | 5 | $96 |
Products named: REZDIFFRA, DUPIXENT, TREMFYA, IBSRELA, RINVOQ, EVARREST, LINZESS, XIFAXAN.
Industry payments across FL — which companies pay providers there.
